<DOC>
	<DOC>NCT01617967</DOC>
	<brief_summary>The purpose of this study is to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of ALN-TTR02 in patients with transthyretin (TTR) mediated amyloidosis (ATTR).</brief_summary>
	<brief_title>Trial to Evaluate Safety and Tolerability of ALN-TTR02 in Transthyretin (TTR) Amyloidosis</brief_title>
	<detailed_description />
	<mesh_term>Amyloidosis</mesh_term>
	<criteria>Body mass index must be between 17 kg/m2 and â‰¤ 33 kg/m2; Women of childbearing potential must have a negative pregnancy test, cannot be breast feeding, and must use appropriate contraception; Males agree to use appropriate contraception; Diagnosis of TTR amyloidosis; Adequate blood counts, liver and renal function; Willing to give written informed consent and are willing to comply with the study requirements. Known human immunodeficiency virus (HIV) positive status or known or suspected systemic bacterial, viral, parasitic, or fungal infection; Received an investigational agent, other than tafamidis or diflunisal, within 30 days prior to first dose study drug administration; Prior liver transplant; Poor cardiac function; Considered unfit for the study by the Principal Investigator; Employee or family member of the sponsor or the clinical study site personnel.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>RNAi therapeutic</keyword>
</DOC>